First Subject Dosed in Lipigon’s Phase I Clinical Study with Antisense Oligonucleotide Candidate Derived from Secarna Pharmaceutical’s LNAplus(TM) Technology PlatformMUNICH and MARTINSRIED, GERMANY / ACCESSWIRE / May 31, 2022 / Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets, is pleased to announce that the Company's partner Lipigon Pharmaceuticals AB ("Lipigon") has advanced their lead candidate, Lipisense , into a phase 1 clinical study . Lipisense is an antisense oligonucleotide (ASO) discovered and developed with Secarna's proprietary LNAplus™ platform for the treatment of rare lipid-related-diseases. The Swedish Medical Products Agency approved the trial last week and the first subject has already been dosed. Progression of the drug candidate into the clinic triggered an undisclosed milestone payment to Secarna.
Secarna Pharmaceuticals' Strategic Partner Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb- The programme designation is based on an antisense-based approach which triggers a US$ 16 M payment to Evotec by Bristol Myers Squibb - Evotec sources LNAplusTM antisense technology through a strategic partnership with Secarna Pharmaceuticals MUNICH and MARTINSRIED, GERMANY / ACCESSWIRE / April 12, 2022 / Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), a biopharmaceutical company focusing on the discovery and development of
Secarna Pharmaceuticals' Partner Denali Therapeutics Exercises Option for LNAplusTM Antisense Oligonucleotide Development Program in Neurodegeneration- First development program for which Denali exercised an option under the ongoing and recently expanded collaboration - Secarna's LNAplusTM antisense oligonucleotides (ASOs) combined with Denali's Oligonucleotide Transport Vehicle (OTV) technology provide potential for novel therapies in the area of difficult-to-treat central nervous system (CNS) diseases MUNICH and MARTINSRIED, GERMANY / ACCESSWIRE / February 22, 2022 / Secarna
Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies- Secarna's LNAplusTM ASOs have the potential to optimize personalized T cell therapies being developed by Achilles - Secarna's industry-leading antisense oligonucleotide (ASO) platform LNAplusTM enables discovery and research of ASOs against undisclosed targets in the area of immune oncology MUNICH, GERMANY and MARTINSRIED, GERMANY / ACCESSWIRE / November 10, 2021 / Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), a biopharmaceutical
Secarna Pharmaceuticals and Denali Therapeutics Expand Strategic Partnership for the Discovery and Development of Novel ASO Therapeutics in the Field of CNS Diseases- Companies broaden use of Secarna's industry-leading ASO discovery and development platform LNAplus TM and Denali's blood-brain barrier Transport Vehicle (TV) technology - Multiple new programs across a range of indications added to the partnership entered into in 2020 MUNICH/MARTINSRIED, GERMANY / ACCESSWIRE / October 26, 2021 / Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), a biopharmaceutical company focusing on the discovery and
Secarna Pharmaceuticals has Initiated a Transnational Scientific Consortium to Identify New Biomarkers for Personalized Cancer Immunotherapy with ASOs- Secarna has joined forces with the Latvian Institute of Organic Synthesis, the leading drug discovery and development center in the Baltics, the Institute of Bioinformatics (Medical University of Innsbruck) and Innoplexus AG, the leading Artificial Intelligence (AI) platform for drug discovery to identify biomarkers correlating with tumor-induced resistance pathways - The consortium aims to further understand the tumor microenvironment and
Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Evotec Expand Strategic Partnership in the Field of Antisense Drug Discovery- In addition to the successful ongoing collaboration on a co-owned LNAplus TM ASO pipeline, Secarna and Evotec now also start to jointly work on third-party discovery, research and development programs - The two companies will leverage Secarna's industry-leading antisense oligonucleotide expertise with Evotec's unparalleled discovery and development capabilities to enable novel development projects for industry partners - Across therapeutic
